1. Rational Design, Structure–Activity Relationship, and Immunogenicity of Hypoallergenic Pru p 3 Variants
- Author
-
Montserrat Fernandez-Rivas, Bettina M. Jensen, Josef Laimer, Gabriele Gadermaier, Isabel Pablos, Antonio Portolés, Fatima Ferreira, Laurian Jongejan, Juan A. Asturias, Serge A. Versteeg, Lars K. Poulsen, Nikolaos G. Papadopoulos, Peter Briza, Adriano Mari, Markus Steiner, Neil M. Rigby, Angelika Hörschläger, Peter Lackner, Stephanie Pauline Eichhorn, Ronald van Ree, Experimental Immunology, AII - Inflammatory diseases, APH - Global Health, APH - Personalized Medicine, Ear, Nose and Throat, and APH - Quality of Care
- Subjects
0301 basic medicine ,Adult ,Pru p 3 ,Adolescent ,In silico ,hypoallergens ,lipid transfer proteins ,03 medical and health sciences ,Structure-Activity Relationship ,Young Adult ,Structure–activity relationship ,Animals ,Humans ,Child ,Protein secondary structure ,Research Articles ,Plant Proteins ,Mice, Inbred BALB C ,030109 nutrition & dietetics ,Chemistry ,Immunogenicity ,Rational design ,Hypoallergenic ,Antigens, Plant ,Immunoglobulin E ,Molecular biology ,Recombinant Proteins ,Disease Models, Animal ,030104 developmental biology ,allergen immunotherapy ,Female ,Immunization ,peach allergies ,Plant lipid transfer proteins ,Food Hypersensitivity ,Food Science ,Biotechnology ,Cysteine ,Research Article - Abstract
Scope Allergies to lipid transfer proteins involve severe adverse reactions; thus, effective and sustainable therapies are desired. Previous attempts disrupting disulfide bonds failed to maintain immunogenicity; thus, the aim is to design novel hypoallergenic Pru p 3 variants and evaluate the applicability for treatment of peach allergy. Methods and results Pru p 3 proline variant (PV) designed using in silico mutagenesis, cysteine variant (CV), and wild‐type Pru p 3 (WT) are purified from Escherichia coli. Variants display homogenous and stable protein conformations with an altered secondary structure in circular dichroism. PV shows enhanced long‐term storage capacities compared to CV similar to the highly stable WT. Using sera of 33 peach allergic patients, IgE‐binding activity is reduced by 97% (PV) and 71% (CV) compared to WT. Both molecules show strong hypoallergenicity in Pru p 3 ImmunoCAP cross‐inhibition and histamine release assays. Immunogenicity of PV is demonstrated with a phosphate‐based adjuvant formulation in a mouse model. Conclusions An in silico approach is used to generate a PV without targeting disulfide bonds, T cell epitopes, or previously reported IgE epitopes of Pru p 3. PV is strongly hypoallergenic while structurally stable and immunogenic, thus representing a promising candidate for peach allergen immunotherapy., Engineering of the lipid transfer protein Pru p 3 from peach results in the generation of stable protein fold variants. These molecules demonstrate very low allergenic potency opposed to the wild‐type allergen. Proline variant presents enhanced integrity and elicits an immune response in a mouse model, thus representing a candidate molecule for allergen immunotherapy of peach allergic patients.
- Published
- 2019